Viral hepatitis: Impressive advances but still a long way to eradication of the disease

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 1-3

  Marcellin, Patrick ^a,b,c   Asselah, Tarik ^a,b,c  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chronic hepatitis; Direct acting antivirals; Fibrosis regression; Hepatitis B virus; Hepatitis C virus; Oral treatment

Indexed keywords

ABT 333; BOCEPREVIR; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; DISEASE ERADICATION; EDITORIAL; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; VIRAL CLEARANCE; VIRUS HEPATITIS;

CHRONIC HEPATITIS; DIRECT-ACTING ANTIVIRALS; FIBROSIS REGRESSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; ORAL TREATMENT;

ANTIVIRAL AGENTS; DISEASE ERADICATION; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS, VIRAL, HUMAN; HUMANS; PREVALENCE;

EID: 84890890477     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12422     Document Type: Editorial

References (28)

1. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-7.
2. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(Suppl 1): 93-104.
3. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
4. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 1997; 127: 875-81.
5. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 3: 821-9.
6. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.
7. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 3: 636-41.
8. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 1: 123-30.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 7262: 399-401.
10. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. PNAS 2008; 19: 7034-9.
11. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 4: 516-24.
12. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub populations in the QUEST 1 and 2 phase III trials. AASLD 2013. Abstract 1122.
13. Jensen D, Asselah T, Dieterich D, et al. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment- naïve patients with chronic hepatitis C genotype-1 infection. AASLD 2013. (Abstract 1088).
14. Jacobson I, Asselah T, Ferenci P, et al. STARTVerso3: a randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. AASLD 2013. (Abstract 1100).
15. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with or without RBV in genotype 1 treatment-naïve and prior null responder patients: COSMOS. Hepatology 2013, AASLD; LB3.
16. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.
17. Lalezari J, Holland L, Glutzer E, et al. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir, and PPI-668, with and without ribavirin, in patients with HCV genotype-1a infection. Hepatology 2013; LB-20.
18. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
19. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment option. N Engl J Med 2013; 368: 1867-77.
20. Asselah T. Sofosbuvir for the treatment of Hepatitis C virus. Expert Opin Pharmacother 2014; 15: 121-30.
21. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
22. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; 56: 527-32.
23. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 318: 468-75.
24. Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol 2013; 28: 912-23.
25. Martinot-Peignoux M, Lapalus M, Laouénan C, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol 2013; 58: 401-7.
26. Martinot-Peignoux M, Carvalho RJ, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e-antigen-positive patients. J Hepatol 2013; 58: 1089-95.
27. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg negative patients. Hepatology 2009; 49: 1151-7.
28. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring the natural history and treatment out come. Liver Int 2013; 33(Supp 1): 125-32.